CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
9.22
0.65%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.06
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Pulmonx Corp ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 9.28
Open* 9.17
1-Year Change* -22.42%
Day's Range* 9.11 - 9.36
52 wk Range 7.75-14.28
Average Volume (10 days) 242.20K
Average Volume (3 months) 5.28M
Market Cap 491.49M
P/E Ratio -100.00K
Shares Outstanding 38.31M
Revenue 64.82M
EPS -1.62
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Feb 20, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 4, 2024 9.22 -0.02 -0.22% 9.24 9.38 9.01
Mar 1, 2024 9.28 0.27 3.00% 9.01 9.48 8.96
Feb 29, 2024 9.18 -0.27 -2.86% 9.45 9.63 9.06
Feb 28, 2024 9.33 -0.67 -6.70% 10.00 10.00 9.31
Feb 27, 2024 10.07 -0.26 -2.52% 10.33 10.40 10.06
Feb 26, 2024 10.36 -0.33 -3.09% 10.69 11.04 10.23
Feb 23, 2024 10.77 -0.51 -4.52% 11.28 11.50 10.53
Feb 22, 2024 11.82 -2.02 -14.60% 13.84 13.88 11.54
Feb 21, 2024 14.44 0.35 2.48% 14.09 14.47 14.09
Feb 20, 2024 14.37 0.13 0.91% 14.24 14.57 14.06
Feb 16, 2024 14.28 -0.10 -0.70% 14.38 14.46 14.23
Feb 15, 2024 14.53 0.02 0.14% 14.51 14.78 14.33
Feb 14, 2024 14.61 0.36 2.53% 14.25 14.67 14.21
Feb 13, 2024 14.24 0.14 0.99% 14.10 14.52 14.05
Feb 12, 2024 14.61 0.43 3.03% 14.18 14.70 14.18
Feb 9, 2024 14.20 0.00 0.00% 14.20 14.43 14.20
Feb 8, 2024 14.30 0.04 0.28% 14.26 14.44 14.22
Feb 7, 2024 14.44 0.00 0.00% 14.44 14.47 14.23
Feb 6, 2024 14.41 0.24 1.69% 14.17 14.52 14.07
Feb 5, 2024 14.28 0.37 2.66% 13.91 14.54 13.89

Pulmonx Corporation Events

Time (UTC) Country Event
Tuesday, April 30, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Pulmonx Corp Earnings Release
Q1 2024 Pulmonx Corp Earnings Release

Forecast

-

Previous

-
Thursday, May 16, 2024

Time (UTC)

15:00

Country

US

Event

Pulmonx Corp Annual Shareholders Meeting
Pulmonx Corp Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 53.662 48.416 32.733 32.595 20.004
Revenue 53.662 48.416 32.733 32.595 20.004
Cost of Revenue, Total 13.797 12.786 11.531 10.181 7.718
Gross Profit 39.865 35.63 21.202 22.414 12.286
Total Operating Expense 112.299 95.72 65.065 50.433 35.056
Selling/General/Admin. Expenses, Total 83.105 69.871 46.074 34.203 20.347
Research & Development 15.397 13.063 7.46 6.049 6.991
Operating Income -58.637 -47.304 -32.332 -17.838 -15.052
Interest Income (Expense), Net Non-Operating 0.063 -1.029 -2.868 -1.785 -2.199
Other, Net 0.004 0.015 3.182 -0.717 -1.216
Net Income Before Taxes -58.57 -48.318 -32.018 -20.34 -18.467
Net Income After Taxes -58.923 -48.661 -32.231 -20.703 -18.479
Net Income Before Extra. Items -58.923 -48.661 -32.231 -20.703 -18.479
Net Income -58.923 -48.661 -32.231 -20.703 -18.479
Income Available to Common Excl. Extra. Items -58.923 -48.661 -32.231 -20.703 -18.479
Income Available to Common Incl. Extra. Items -58.923 -48.661 -32.231 -20.703 -18.479
Diluted Net Income -58.923 -48.661 -32.231 -20.703 -18.479
Diluted Weighted Average Shares 37.0965 36.1294 35.6937 33.9254 33.9254
Diluted EPS Excluding Extraordinary Items -1.58837 -1.34685 -0.90299 -0.61025 -0.54469
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.58837 -1.34685 -0.90299 -0.61025 -0.54469
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 17.194 14.535 15.425 13.502 13.95
Revenue 17.194 14.535 15.425 13.502 13.95
Cost of Revenue, Total 4.46 3.946 4.241 3.35 3.532
Gross Profit 12.734 10.589 11.184 10.152 10.418
Total Operating Expense 33.633 30.935 30.052 27.433 28.361
Selling/General/Admin. Expenses, Total 23.463 22.736 21.908 19.717 21.235
Research & Development 5.71 4.253 3.903 4.366 3.594
Operating Income -16.439 -16.4 -14.627 -13.931 -14.411
Interest Income (Expense), Net Non-Operating 0.346 0.656 0.589 -0.209 -0.224
Other, Net 0.038 0.008 0.001 -0.032 0.035
Net Income Before Taxes -16.055 -15.736 -14.037 -14.172 -14.6
Net Income After Taxes -16.195 -15.86 -14.283 -14.172 -14.64
Net Income Before Extra. Items -16.195 -15.86 -14.283 -14.172 -14.64
Net Income -16.195 -15.86 -14.283 -14.172 -14.64
Income Available to Common Excl. Extra. Items -16.195 -15.86 -14.283 -14.172 -14.64
Income Available to Common Incl. Extra. Items -16.195 -15.86 -14.283 -14.172 -14.64
Diluted Net Income -16.195 -15.86 -14.283 -14.172 -14.64
Diluted Weighted Average Shares 37.8183 37.5724 37.3828 37.1903 37.0034
Diluted EPS Excluding Extraordinary Items -0.42823 -0.42212 -0.38207 -0.38107 -0.39564
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.42823 -0.42212 -0.38207 -0.38107 -0.39564
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 168.953 208.002 249.989 41.071 11.308
Cash and Short Term Investments 141.138 180.041 231.561 28.347 4.124
Cash 97.089 141.239 221.028 7.449 4.073
Cash & Equivalents 4.647 0.831 10.533 6.318 0.051
Short Term Investments 39.402 37.971 0 14.58 0
Total Receivables, Net 9.279 6.924 4.567 5.898 3.421
Accounts Receivable - Trade, Net 8.677 6.562 4.228 5.511 2.95
Total Inventory 14.564 16.285 10.741 5.612 3.32
Prepaid Expenses 3.451 4.174 2.512 0.448 0.318
Other Current Assets, Total 0.521 0.578 0.608 0.766 0.125
Total Assets 193.676 235.173 263.708 53.533 15.013
Property/Plant/Equipment, Total - Net 10.5 12.889 10.45 7.463 0.375
Property/Plant/Equipment, Total - Gross 14.056 15.132 12.223 8.903 2.12
Accumulated Depreciation, Total -3.556 -2.243 -1.773 -1.44 -1.745
Goodwill, Net 2.333 2.333 2.333 2.333 2.333
Intangibles, Net 0.154 0.277 0.4 0.524 0.647
Other Long Term Assets, Total 5.812 0.731 0.536 2.142 0.35
Total Current Liabilities 18.492 17.55 12.526 14.161 8.072
Accounts Payable 1.758 1.582 1.472 2.681 1.289
Accrued Expenses 15.988 14.345 9.624 9.125 5.496
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.656 1.532 1.43 2.355 1.287
Total Liabilities 39.669 41.934 37.574 35.572 41.804
Total Long Term Debt 17.234 17.324 17.368 14.965 33.605
Long Term Debt 17.234 17.324 17.368 14.965 33.605
Deferred Income Tax 0.094 0.037 0.062 0.043 0.048
Other Liabilities, Total 3.849 7.023 7.618 6.403 0.079
Total Equity 154.007 193.239 226.134 17.961 -26.791
Preferred Stock - Non Redeemable, Net 0 0 0 205.339 140.535
Common Stock 0.038 0.037 0.036 0.019 0.017
Additional Paid-In Capital 502.712 482.885 467.147 21.733 21.124
Retained Earnings (Accumulated Deficit) -350.318 -291.395 -242.734 -210.503 -189.8
Other Equity, Total 1.575 1.712 1.685 1.373 1.333
Total Liabilities & Shareholders’ Equity 193.676 235.173 263.708 53.533 15.013
Total Common Shares Outstanding 37.5556 36.9318 35.6937 33.9254 33.9254
Long Term Investments 5.924 10.941
Current Port. of LT Debt/Capital Leases 0.09 0.091
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 147.364 164.428 181.298 168.953 183.111
Cash and Short Term Investments 116.482 135.152 152.836 141.138 156.899
Cash 67.777 76.596 84.95 97.089 107.308
Cash & Equivalents 27.168 24.985 25.457 4.647 2.849
Short Term Investments 21.537 33.571 42.429 39.402 46.742
Total Receivables, Net 10.92 9.83 8.845 9.279 7.619
Accounts Receivable - Trade, Net 10.091 8.941 8.171 8.677 7.221
Total Inventory 16.131 15.636 15.588 14.564 15.568
Prepaid Expenses 3.402 3.226 3.651 3.451 2.611
Other Current Assets, Total 0.429 0.584 0.378 0.521 0.414
Total Assets 185.016 193.113 201.272 193.676 202.203
Property/Plant/Equipment, Total - Net 8.126 8.924 9.642 10.5 11.328
Property/Plant/Equipment, Total - Gross 12.765 13.208 13.559 14.056 14.529
Accumulated Depreciation, Total -4.639 -4.284 -3.917 -3.556 -3.201
Goodwill, Net 2.333 2.333 2.333 2.333 2.333
Intangibles, Net 0.062 0.092 0.123 0.154 0.185
Long Term Investments 23.271 12.454 2.637 5.924 0
Other Long Term Assets, Total 3.86 4.882 5.239 5.812 5.246
Total Current Liabilities 20.485 19.521 17.079 18.492 21.686
Accounts Payable 3.189 2.377 2.89 1.758 2.648
Accrued Expenses 16.765 16.571 13.595 15.988 13.211
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.091 0.093 0.091 0.09 5.043
Other Current Liabilities, Total 0.44 0.48 0.503 0.656 0.784
Total Liabilities 59.273 59.161 57.338 39.669 38.721
Total Long Term Debt 37.154 37.147 37.173 17.234 12.34
Long Term Debt 37.154 37.147 37.173 17.234 12.34
Deferred Income Tax 0.097 0.094 0.071 0.094 0.051
Other Liabilities, Total 1.537 2.399 3.015 3.849 4.644
Total Equity 125.743 133.952 143.934 154.007 163.482
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.038 0.038 0.038 0.038 0.037
Additional Paid-In Capital 521.034 514.331 508.254 502.712 498.083
Retained Earnings (Accumulated Deficit) -397.273 -382.373 -366.178 -350.318 -336.035
Other Equity, Total 1.944 1.956 1.82 1.575 1.397
Total Liabilities & Shareholders’ Equity 185.016 193.113 201.272 193.676 202.203
Total Common Shares Outstanding 38.3014 38.0167 37.7307 37.5556 37.408
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -58.923 -48.661 -32.231 -20.703 -18.479
Cash From Operating Activities -45.083 -41.388 -30.633 -20.765 -18.394
Cash From Operating Activities 1.513 0.867 0.483 0.365 0.27
Non-Cash Items 19.341 14.252 5.902 1.974 1.338
Cash Taxes Paid 0.398 0.322 0.259 0.196 0.226
Cash Interest Paid 0.847 0.722 3.059 1.396 1.361
Changes in Working Capital -7.014 -7.846 -4.787 -2.401 -1.523
Cash From Investing Activities -4.225 -46.255 12.694 -14.233 0.2
Capital Expenditures -1.318 -3.671 -0.911 -0.72 -0.316
Other Investing Cash Flow Items, Total -2.907 -42.584 13.605 -13.513 0.516
Cash From Financing Activities 2.419 4.456 234.831 45.619 12.114
Financing Cash Flow Items -0.053 -0.041 -4.499 -0.568 0
Issuance (Retirement) of Stock, Net 2.559 4.497 206.337 40.187 0.114
Issuance (Retirement) of Debt, Net -0.087 0 32.993 6 12
Foreign Exchange Effects 0.145 0.106 0.133 0.022 0.154
Net Change in Cash -46.744 -83.081 217.025 10.643 -5.926
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -15.86 -58.923 -44.64 -30.468 -15.828
Cash From Operating Activities -12.644 -45.083 -35.277 -24.59 -15.026
Cash From Operating Activities 0.437 1.513 1.127 0.744 0.368
Non-Cash Items 5.373 19.341 14.434 9.286 4.212
Cash Taxes Paid 0.092 0.398 0.337 0.228 0.029
Cash Interest Paid 0.00036 0.847 0.628 0.375 0.178
Changes in Working Capital -2.594 -7.014 -6.198 -4.152 -3.778
Cash From Investing Activities 0.574 -4.225 -3.498 -3.542 -5.622
Capital Expenditures -0.061 -1.318 -1.142 -0.863 -0.564
Other Investing Cash Flow Items, Total 0.635 -2.907 -2.356 -2.679 -5.058
Cash From Financing Activities 20.72 2.419 2.352 1.446 1.315
Financing Cash Flow Items -0.053 0 0 0
Issuance (Retirement) of Stock, Net 0.72 2.559 2.396 1.49 1.315
Issuance (Retirement) of Debt, Net 20 -0.087 -0.044 -0.044
Foreign Exchange Effects 0.021 0.145 0.345 0.153 0.021
Net Change in Cash 8.671 -46.744 -36.078 -26.533 -19.312
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
PRIMECAP Management Company Investment Advisor 14.515 5519721 17000 2023-06-30
Point72 Asset Management, L.P. Hedge Fund 8.7464 3326065 242815 2023-06-30 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.0208 2289587 198017 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.2557 1998614 -590541 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 4.2811 1628005 665507 2023-06-30 LOW
Morgan Stanley & Co. LLC Research Firm 3.5521 1350793 -370855 2023-06-30 MED
Deerfield Management Company, L.P. Hedge Fund 2.7987 1064285 -1338419 2023-06-30 MED
Braidwell LP Hedge Fund 2.628 999362 -163932 2023-06-30 HIGH
Kleiner, Perkins, Caufield & Byers Venture Capital 2.6164 994971 0 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.5971 987616 40639 2023-06-30 LOW
Victory Capital Management Inc. Investment Advisor/Hedge Fund 2.5701 977344 977344 2023-06-30 LOW
French (Glendon E III) Individual Investor 2.4103 916595 -6527 2023-09-01 LOW
BNP Paribas Asset Management USA, Inc. Investment Advisor 2.3872 907792 -69239 2023-06-30 LOW
BNP Paribas Asset Management UK Limited Investment Advisor 2.3602 897525 0 2023-09-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.938 736993 36851 2023-06-30 LOW
Franklin Advisers, Inc. Investment Advisor/Hedge Fund 1.9137 727752 17494 2023-06-30 LOW
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 1.9083 725667 46928 2023-06-30 MED
D. E. Shaw & Co., L.P. Hedge Fund 1.8838 716378 142214 2023-06-30 MED
Rock Springs Capital Management LP Hedge Fund 1.7156 652400 0 2023-06-30 LOW
Pura Vida Investments, LLC Hedge Fund 1.6735 636408 -1105 2023-06-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Pulmonx Corporation Company profile

About Pulmonx Corp

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Pulmonx Corp revenues increased 48% to $48.4M. Net loss increased 51% to $48.7M. Revenues reflect United States segment increase of 54% to $25M, Europe, Middle-East and Africa ("EMEA") segment increase of 44% to $19.9M. Higher net loss reflects Selling, general and administrative increase of 41% to $61.2M (expense), Stock-based Compensation in SGA increase from $2.8M to $8.7M (expense).

Industry: Medical Equipment

700 Chesapeake Dr
REDWOOD CITY
CALIFORNIA 94063
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

BTC/USD

67,145.60 Price
-0.620% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

18,129.90 Price
-0.400% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Gold

2,115.48 Price
+0.050% 1D Chg, %
Long position overnight fee -0.0189%
Short position overnight fee 0.0107%
Overnight fee time 22:00 (UTC)
Spread 0.30

Oil - Crude

77.98 Price
-0.500% 1D Chg, %
Long position overnight fee 0.0260%
Short position overnight fee -0.0479%
Overnight fee time 22:00 (UTC)
Spread 0.040

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading